ARS Pharmaceuticals (SPRY) Stock: Buy, Sell, or Hold?
SPRY - ARS Pharmaceuticals, Inc. Common Stock
$4.04
-0.28 (-6.48%)
âŧ
5d:
+0.5%
30d:
-2.65%
90d:
-29.86%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 09, 2026
16d
Get Alerted When SPRY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SPRY is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SPRY is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SPRY is currently trading at $4.04, which is considered slightly low relative to its 30-day fair value range of $4.07 to $4.37.
Technical Outlook: Technically, SPRY is in a strong downtrend. Immediate support is located at $3.81, while resistance sits at $4.44. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.50 (+420.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRY is in a strong downtrend. Immediate support is located at $3.81, while resistance sits at $4.44. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.50 (+420.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.07 -
$4.37
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 420.8% below Wall St target ($22.50)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.07 -
$4.37
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.81
Resistance Level
$4.44
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.82
Wall Street Target
$22.50
(+420.8%)
Revenue Growth (YoY)
114.2%
Profit Margin
-184.2%
Share & Embed Analysis
Last updated: October 23, 2026 3:40 PM ET
Data refreshes hourly during market hours. Next update: 4:40 PM
Data refreshes hourly during market hours. Next update: 4:40 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
RYTM
Rhythm Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$144 | 75 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
